Melanoma patients with CAFs expressing podoplanin, a mucin-type transmembrane protein, have tumors with greater tumor thickness, more lymph node metastases and poorer survival than patients with podoplanin-negative CAFs [446]. This evidence concerns the gene PDPN and neoplasm.